Company intelligence / Profile preview

SwiftScale Biologics

San Leandro, California, United States

Ownership: Private
Employees: ~3
Development stage: Other

Overview

SwiftScale Biologics focused on enabling rapid, low-cost manufacturing of protein therapeutics (including monoclonal antibodies) using cell-free and bacterial production platforms; it is described as a manufacturing and enabling-technology company rather than a therapeutic developer, with no disclosed proprietary clinical programs, but it successfully produced a COVID-19 antibody candidate from DNA sequence to clinical doses in months.[1][2][4]

Therapeutic areas: Infectious Diseases
Modalities: BiologicProteinMonoclonal antibody
Industry: Contract Manufacturing Organization

Partnerships

Resilience (acquisition and integration of CFPS technology)[2][3]Partner labs and companies supplying COVID-19 antibodies for scale-up manufacturing[4]

Beyond the preview

Go deeper on SwiftScale Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SwiftScale Biologics.

Explore the full profile